Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression
- 15 December 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (24), 7376-7386
- https://doi.org/10.1158/0008-5472.can-11-1154
Abstract
Although alterations in xenobiotic metabolism are considered causal in the development of bladder cancer, the precise mechanisms involved are poorly understood. In this study, we used high-throughput mass spectrometry to measure over 2,000 compounds in 58 clinical specimens, identifying 35 metabolites which exhibited significant changes in bladder cancer. This metabolic signature distinguished both normal and benign bladder from bladder cancer. Exploratory analyses of this metabolomic signature in urine showed promise in distinguishing bladder cancer from controls and also nonmuscle from muscle-invasive bladder cancer. Subsequent enrichment-based bioprocess mapping revealed alterations in phase I/II metabolism and suggested a possible role for DNA methylation in perturbing xenobiotic metabolism in bladder cancer. In particular, we validated tumor-associated hypermethylation in the cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1B1 (CYP1B1) promoters of bladder cancer tissues by bisulfite sequence analysis and methylation-specific PCR and also by in vitro treatment of T-24 bladder cancer cell line with the DNA demethylating agent 5-aza-2′-deoxycytidine. Furthermore, we showed that expression of CYP1A1 and CYP1B1 was reduced significantly in an independent cohort of bladder cancer specimens compared with matched benign adjacent tissues. In summary, our findings identified candidate diagnostic and prognostic markers and highlighted mechanisms associated with the silencing of xenobiotic metabolism. The metabolomic signature we describe offers potential as a urinary biomarker for early detection and staging of bladder cancer, highlighting the utility of evaluating metabolomic profiles of cancer to gain insights into bioprocesses perturbed during tumor development and progression. Cancer Res; 71(24); 7376–86. ©2011 AACR.Keywords
Other Versions
This publication has 25 references indexed in Scilit:
- Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer CellsPLOS ONE, 2011
- A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor ProgressionJNCI Journal of the National Cancer Institute, 2010
- Statistical consideration for clinical biomarker research in bladder cancerUrologic Oncology: Seminars and Original Investigations, 2010
- Quantitative Proteomic Profiling of Prostate Cancer Reveals a Role for miR-128 in Prostate CancerMolecular & Cellular Proteomics, 2010
- A Case–Control Study of Smoking and Bladder Cancer Risk: Emergent Patterns Over TimeJNCI Journal of the National Cancer Institute, 2009
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionNature, 2009
- Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancerClinical and Experimental Medicine, 2008
- Detection of Bladder Cancer in Human Urine by Metabolomic Profiling Using High Performance Liquid Chromatography/Mass SpectrometryJournal of Urology, 2008
- Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarraysBritish Journal of Cancer, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001